News for PTCT Stock

PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results PTC518 PIVOT-HD Study Achieves Primary Endpoint PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results PTC Therapeutics to Participate in Upcoming Investor Conferences PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich's Ataxia PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results CHMP Maintains Negative Opinion on Translarna™ Reexamination PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients PTC Therapeutics to Participate at Upcoming Investor Conference PTC Therapeutics Announces Validation of Sepiapterin European MAA PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™ PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA PTC Therapeutics Provides Key Regulatory Updates PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce CHMP Delivers Opinion on Translarna™ for Conversion to Full Authorization PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics to Present Recent Data for Sepiapterin at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium PTC Therapeutics Provides Corporate Update and Reports Second Quarter Financial Results CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial PTC Therapeutics Announces Strategic Pipeline Prioritization PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation PTC Therapeutics to Participate at Upcoming Investor Conference NICE Recommends Reimbursement for Translarna™ PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results  PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518 PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference PTC Therapeutics to Participate at Upcoming Investor Conferences PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Participate at Upcoming Virtual Investor Conference PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results PTC Therapeutics to Participate at Upcoming Virtual Investor Conference PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility Tegsedi® Receives Innovative Drug Category Pricing in Brazil PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™ PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia PTC Therapeutics to Participate at Upcoming Virtual Investor Conference New Data Shows Devastating Impact of AADC Deficiency on Caregivers PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PTC Therapeutics to Host Conference Call to Discuss First Quarter 2021 Financial Results PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™ PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™ PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants with Type 1 Spinal Muscular Atrophy Published in The New England Journal of Medicine PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19 PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results PTC Therapeutics to Host Call to Review Results from its Study of Translarna™ (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference PTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Host Translarna™ Deep Dive Webinar PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2020 Financial Results Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations PTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam) PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update PTC Therapeutics Announces the Initiation of a Phase 2/3 Clinical Trial to Evaluate PTC299 for the Treatment of COVID-19 PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results